» Articles » PMID: 16452185

Extracellular Signal-regulated Kinase 1/2 Mitogen-activated Protein Kinase Pathway is Involved in Myostatin-regulated Differentiation Repression

Overview
Journal Cancer Res
Specialty Oncology
Date 2006 Feb 3
PMID 16452185
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

The cytokines of transforming growth factor beta (TGF-beta) and its superfamily members are potent regulators of tumorigenesis and multiple cellular events. Myostatin is a member of TGF-beta superfamily and plays a negative role in the control of cell proliferation and differentiation. We now show that myostatin rapidly activated the extracellular signal-regulated kinase 1/2 (Erk1/2) cascade in C2C12 myoblasts. A more remarkable Erk1/2 activation stimulated by myostatin was observed in differentiating cells than proliferating cells. The results also showed that Ras was the upstream regulator and participated in myostatin-induced Erk1/2 activation because the expression of a dominant-negative Ras prevented myostatin-mediated inhibition of Erk1/2 activation and proliferation. Importantly, the myostatin-suppressed myotube fusion and differentiation marker gene expression were attenuated by blockade of Erk1/2 mitogen-activated protein kinase (MAPK) pathway through pretreatment with MAPK/Erk kinase 1 (MEK1) inhibitor PD98059, indicating that myostatin-stimulated activation of Erk1/2 negatively regulates myogenic differentiation. Activin receptor type IIb (ActRIIb) was previously suggested as the only type II membrane receptor triggering myostatin signaling. In this study, by using synthesized small interfering RNAs and dominant-negative ActRIIb, we show that myostatin failed to stimulate Erk1/2 phosphorylation and could not inhibit myoblast differentiation in ActRIIb-knockdown C2C12 cells, indicating that ActRIIb was required for myostatin-stimulated differentiation suppression. Altogether, our findings in this report provide the first evidence to reveal functional role of the Erk1/2 MAPK pathway in myostatin action as a negative regulator of muscle cell growth.

Citing Articles

Pathogenesis of Sarcopenia in Chronic Kidney Disease-The Role of Inflammation, Metabolic Dysregulation, Gut Dysbiosis, and microRNA.

Bakinowska E, Olejnik-Wojciechowska J, Kielbowski K, Skoryk A, Pawlik A Int J Mol Sci. 2024; 25(15).

PMID: 39126043 PMC: 11313360. DOI: 10.3390/ijms25158474.


Bone-muscle crosstalk under physiological and pathological conditions.

Dong Y, Yuan H, Ma G, Cao H Cell Mol Life Sci. 2024; 81(1):310.

PMID: 39066929 PMC: 11335237. DOI: 10.1007/s00018-024-05331-y.


Expression profiling by high-throughput sequencing reveals GADD45, SMAD7, EGR-1 and HOXA3 activation in Myostatin (MSTN) and GDF11 treated myoblasts.

Braun P, Alawi M, Saygi C, Pantel K, Wagers A Genet Mol Biol. 2024; 47(2):e20230304.

PMID: 39012095 PMC: 11256782. DOI: 10.1590/1678-4685-GMB-2023-0304.


Inflammatory Cytokine-Induced Muscle Atrophy and Weakness Can Be Ameliorated by an Inhibition of TGF-β-Activated Kinase-1.

Kanai M, Ganbaatar B, Endo I, Ohnishi Y, Teramachi J, Tenshin H Int J Mol Sci. 2024; 25(11).

PMID: 38891908 PMC: 11172090. DOI: 10.3390/ijms25115715.


Palmitate-Induced Inflammation and Myotube Atrophy in C2C12 Cells Are Prevented by the Whey Bioactive Peptide, Glycomacropeptide.

de Hart N, Petrocelli J, Nicholson R, Yee E, Ferrara P, Bastian E J Nutr. 2023; 153(10):2915-2928.

PMID: 37652286 PMC: 10731921. DOI: 10.1016/j.tjnut.2023.08.033.